Patent 11746150 was granted and assigned to Surrozen on September, 2023 by the United States Patent and Trademark Office.
The present invention provides anti-LRP5/6 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for treating diseases and disorders associated with Wnt pathway signaling.